Search research articles
Contact Us
Filters
Showing results (31-40 of 82) with videos related to
Page
of 9
Sort By:
Cancers
|
August 14, 2025
Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)
Yvonne Efebera, Vera Suman, Shira Dinner, et al.
Current Hematologic Malignancy Reports
|
October 16, 2012
New proteasome inhibitors in myeloma
Panisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.
British Journal of Haematology
|
September 14, 2012
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
Steffen Klippel, Jana Jakubikova, Jake Delmore, et al.
Blood
|
July 25, 2025
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, et al.
British Journal of Haematology
|
July 8, 2011
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings
Paul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Leukemia & Lymphoma
|
June 14, 2022
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma
Matthew Ho, Maria Moscvin, Soon Khai Low, et al.
Blood
|
January 17, 2013
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Güllü Topal Görgün, Gregory Whitehill, Jennifer L Anderson, et al.
Blood Advances
|
July 26, 2024
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Peter Voorhees, Vera Suman, Yvonne Efebera, et al.
British Journal of Haematology
|
October 20, 2017
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
Michael G Fradley, John D Groarke, Jacob Laubach, et al.
The Lancet. Haematology
|
April 27, 2024
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 82) with videos related to
Sort By:
Page
of 9
Cancers
|
August 14, 2025
Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)
Yvonne Efebera, Vera Suman, Shira Dinner, et al.
Current Hematologic Malignancy Reports
|
October 16, 2012
New proteasome inhibitors in myeloma
Panisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.
British Journal of Haematology
|
September 14, 2012
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
Steffen Klippel, Jana Jakubikova, Jake Delmore, et al.
Blood
|
July 25, 2025
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, et al.
British Journal of Haematology
|
July 8, 2011
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings
Paul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Leukemia & Lymphoma
|
June 14, 2022
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma
Matthew Ho, Maria Moscvin, Soon Khai Low, et al.
Blood
|
January 17, 2013
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Güllü Topal Görgün, Gregory Whitehill, Jennifer L Anderson, et al.
Blood Advances
|
July 26, 2024
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Peter Voorhees, Vera Suman, Yvonne Efebera, et al.
British Journal of Haematology
|
October 20, 2017
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
Michael G Fradley, John D Groarke, Jacob Laubach, et al.
The Lancet. Haematology
|
April 27, 2024
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, et al.
Page
of 9